Results 241 to 250 of about 74,223 (272)

Immunosuppressive Activity of Concanavalin A

Science, 1969
Two strains of mice (C-57 B1 and DBA) were given skin allografts from Swiss ICR/HA mice and were treated with varying doses of concanavalin A; the dosage ranged from only two injections of 25 micrograms during the experiment to daily doses of 1000 micrograms intraperitoneally.
G L Gitnick, R E Ritts, H Markowitz, D A Person   +3 more
openaire   +4 more sources

Effect of concanavalin A and succinyl concanavalin A on cytomegalovirus replication in fibroblasts

Archives of Virology, 1986
In order to investigate inhibition of viral replication, human embryonic fibroblasts infected with cytomegalovirus (CMV) were treated with 0 to 25 micrograms/ml concanavalin A (Con A) and 0 to 150 micrograms/ml succinylated Con A (S-Con A). Alterations in cellular morphology occurred by day 2 post infection (p.i.) in cultures treated with 10 micrograms/
Mary Norval, Ann Grail
openaire   +3 more sources

Concanavalin A as a carrier of daunomycin

Nature, 1977
ONE possible approach for increasing the effectiveness of anti-tumour drugs would be to find methods of altering their distribution in the body to increase their local concentration at the tumour cell sites. Ghose et al. have reported the suppression of Ehrlich ascites carcinoma in mice after administration of chlorambucil allegedly bound to anti ...
Kitao, T, Hattori, K
openaire   +3 more sources

The luminescence properties of concanavalin A

Biochimica et Biophysica Acta (BBA) - Protein Structure, 1975
1. The luminescence properties of native concanavalin A, both at room temperature and at 77 degrees K, are similar to those of other proteins containing tyrosine and tryptophan. 2. Binding of methyl alpha-D-glucopyranoside to concanavalin A causes a slight reduction of its fluorescence at room temperature. 3.
J.N. Miller, G.I.C. Nwokedi
openaire   +3 more sources

Allergenicity of Concanavalin A in Mice

International Archives of Allergy and Immunology, 1979
Concanavalin A (Con A) is a potent allergen in certain strains of mice and in particularly the H-2K^k mice, A/J, CBA/H, and C3H/He. Using a dose of 100 <i>μ</i>g, the subcutaneous route of injection was the most effective means of inducing high, persistent titers of T cell-dependent circulating anti-Con A reagins ...
Graham F. Mitchell, Adrienne E. Clarke
openaire   +3 more sources

Immunosuppressive Activity of Concanavalin A

International Archives of Allergy and Immunology, 1976
Daily intraperitoneal doses of concanavalin A (Con A) produced a dose-related inhibition of adjuvant-induced arthritis in rats. Con A was also effective on established arthritis, markedly relieving the disease after only three doses. The inhibitory effect of Con A was neutralised by pre-incubation with ovalbumin, although this treatment did not modify ...
A K Delitheos, G B West
openaire   +2 more sources

Traffic and assembly of concanavalin A

Trends in Biochemical Sciences, 1988
Abstract Concanavalin A (ConA) is synthesized and packaged into protein bodies during jackbean development. Recent results have shown that traffic of proteins within the plant cells can be disrupted by monensin, when lectin precursors are mis-routed to the cell surface instead of targeted to their correct intracellular destination.
Dianna J. Bowles, Darryl J. Pappin
openaire   +3 more sources

The interaction of platelets and concanavalin A

Thrombosis Research, 1975
Abstract The interaction of agglutinating concanavalin A and non-agglutinating trypsinized concanavalin A preparations with platelet surfaces was monitored by determining the gel electrophoretic labelling pattern of platelet membrane protein obtained from iodinated cells pre-incubated with the plant lectin.
Ralph L. Nachman, Karen L. Kaplan
openaire   +3 more sources

Effect of Concanavalin A on Phagocytosis [PDF]

Nature New Biology, 1972
Concanavalin A has been shown to inhibit phagocytosis by polymorphonuclear leucocytes. The effect is reversed by specific sugars.
openaire   +2 more sources

Concanavalin A: An Introduction

1975
During the last quarter of the nineteenth century and in the beginning of the twentieth century, bacteriologists were searching for agglutinins which could be used as antibacterial agents. Field and Teague (1907), for example, were working with typhoid agglutinins. Kolmer (1923) was working with various other types of antibacterial agglutinins.
openaire   +3 more sources